93106-60-6 Usage
Brand Name(s) in US
Baytril
Veterinary fluoroquinolone antimicrobial agents
Enrofloxacin and sarafloxacin, danofloxacin, difloxacin, ofloxacin, norfloxacin, orbifloxacin are commonly used third-generation fluoroquinolone broad-spectrum antimicrobial agents in veterinary clinic at present , is ethyl compound of ciprofloxacin, also known as ethyl ciprofloxacin, ethyl ciprofloxacin, norfloxacin, is effective on Gram-negative bacteria, Gram-positive bacteria and mycoplasma, its antibacterial activity is significantly superior to norfloxacin, the effect on mycoplasma is stronger than tylosin and Tiamulin Fumarate. This product is oral, intramuscular and subcutaneous injection, and is easily absorbed, widely distributed in vivo, in addition to the central nervous system, the concentration of the drug in other organizations, almost all are higher than the blood concentration. De ethylation in vivo, mainly produced active metabolite ciprofloxacin, but different among the animals metabolism are larger, birds, dogs, rabbits and cattle body's metabolic rates are high, horses and pigs body's metabolic rates are lower. Clinically Enrofloxacin is used for the treatment of various mycoplasma disease, and respiratory system, digestive system and urogenital system infections, skin infections and sepsis caused by E. coli, Salmonella, Haemophilus, Erysipelas bacillus, Staphylococcus, Streptococcus etc. Especially suitable for mixing infections caused by a variety of bacteria.
Spatial structure formulae diagram of Enrofloxacin
The above information is edited by the lookchem of Liu Yujie.
Reasonable compatibility
1. Cooperated application of Enrofloxacin with aminoglycoside (gentamicin), third-generation cephalosporins (cefotaxime, ceftriaxone) and penicillin, colistin, may have synergistic antibacterial effect on certain bacteria (especially Pseudomonas aeruginosa or Enterobacteriaceae), in addition to penicillin-type drugs, due to enhanced toxicity, when in combination, need to reduce the dose, and administered separately.
2. Antibacterial activity of Enrofloxacin combined with apramycin enhanced, showed a synergistic effect. The reason was that antibacterial mechanism of apramycin was to specifically hinder biosynthesis of bacterial protein, and thus achieved effect on inhibiting and killing bacteria, while Enrofloxacin could specifically act on subunit A of bacterial DNA gyrase, inhibiting its activity, affecting DNA melting and sealing chain, both of combination had double blocking effect on bacterial replication and translation process.
3. at the same day were successively mixed to drink with colistin sulfate, can improve the efficacy of Enrofloxacin on chicken bacterial disease. and compatibility with SD silver used for the topical treatment of otitis in dogs.
Reference data: Zheng Hugong, Cui Yaoming editor. reasonable compatibility use of veterinary, Zhengzhou: Henan Science and Technology Press, 2009.
Incompatibility
1. Enrofloxacin can inhibit metabolism of theophylline and caffeine, make the blood concentration increase, thereby causing toxic reactions.
2. Combined with anticholinergic drugs (atropine, 654-2) and H2 receptor antagonists (cimetidine, famotidine), making the bioavailability of Enrofloxacin reduce.
3. Enrofloxacin has a role in inhibiting liver drug enzymes, in combination with drugs metabolized in the liver such as erythromycin, lincomycin, etc. making its clearance decrease, blood concentration increased.
4. antacids may reduce absorption of Enrofloxacin in the gastrointestinal tract, not suitable for simultaneous use.
5. mixed with strongly acidic liquid and the strong alkaline liquid and precipitated.
6. Enrofloxacin and metoclopramide occur chemical changes, easy to turn into muddy, should not be mixed injection.
Side effects
Toxicity of Enrofloxacin is less, safe for clinical use. Therapeutic doses have non-teratogenic and mutagenic effect. Can make young animals cartilage occur turbid, causing lameness and pain. Digestive system reactions are vomiting, abdominal pain and bloating. Skin reactions are erythema, pruritus, urticaria and photosensitivity reactions, etc.
Precautions
1. Enrofloxacin aqueous solution was met with light and easy to change color and decompose, should be kept in dark place.
2. Drug-resistant strains of the product showed an increasing trend, not used at sub-therapeutic doses for long-term.
3. Antacids can inhibit the absorption of this product, should be avoided drinking at the same time.
4. In clinical application, can appropriately adjust dosage based on disease, concentration range of drinking water in poultry, per liter of water, added 25 to 100 mg.
5. withdrawal period of chicken is 8 days. Disabled in egg producing period of laying hen.
6. chicks are very sensitive to Enrofloxacin injection, had many poisoning report, the dose should be strictly controlled.
Uses
Different sources of media describe the Uses of 93106-60-6 differently. You can refer to the following data:
1. 1. Antimicrobial, for bacteria and mycoplasma infection.
2. New veterinary antimicrobial drugs, broad-spectrum, high efficiency, has special effects on Gram-positive and Gram-negative bacteria and mycoplasma.
2. Enrofloxacin is a broad spectrum antibiotic bactericidal agent used in veterinary medicine to treat animals afflicted with certain bacterial infections.
Chemical Properties
Pale Yellow Crystals
Definition
ChEBI: A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary ant
bacterial agent used for the treatment of pets.
Brand name
Baytril (Bayer).
Veterinary Drugs and Treatments
Enrofloxacin is approved for use in dogs and cats (oral only) for
the management
of diseases associated with bacteria susceptible to
enrofloxacin. Because of the dosage restriction (5 mg/kg) for cats,
enrofloxacin is generally used in this species only for the most susceptible
bacterial infections. It is also been approved for use in cattle
(not dairy cattle or veal calves).
Check Digit Verification of cas no
The CAS Registry Mumber 93106-60-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,1,0 and 6 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 93106-60:
(7*9)+(6*3)+(5*1)+(4*0)+(3*6)+(2*6)+(1*0)=116
116 % 10 = 6
So 93106-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C19H22FN3O3/c1-2-21-5-7-22(8-6-21)17-10-16-13(9-15(17)20)18(24)14(19(25)26)11-23(16)12-3-4-12/h9-12H,2-8H2,1H3,(H,25,26)
93106-60-6Relevant articles and documents
Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: Antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity
Marquez, Beatrice,Pourcelle, Vincent,Vallet, Coralie M.,Mingeot-Leclercq, Marie-Paule,Tulkens, Paul M.,Marchand-Bruynaert, Jacqueline,Van Bambeke, Francoise
, p. 1290 - 1301 (2014)
Purpose: To evaluate pharmacological properties (antibacterial activity; accumulation in phagocytic cells; activity against intracellular bacteria; susceptibility to fluoroquinolone efflux transporters) of ciprofloxacin derivatives modified at C-7 of the
A norfloxacin, ciprofloxacin and enrofloxacin synthetic method
-
Paragraph 0008; 0034-0039; 0044; 0045, (2019/07/10)
The present invention provides a norfloxacin, ciprofloxacin and enrofloxacin preparation method, which comprises the carboxylic acid and piperazine in the solvent under the catalytic action of the catalyst in the reaction step, the catalyst is AlBr3 , FeBr3 , ZnBr2 , CuBr2 Or SnBr4 , It has high yield, low cost and the advantage of energy saving and emission reduction.
A norfloxacin, ciprofloxacin and enrofloxacin preparation method
-
Paragraph 0125-0126, (2017/04/25)
The invention discloses a preparation method of norfloxacin, ciprofloxacin and enrofloxacin. The preparation method comprises the following steps: directly reacting 1-ethyl-6-fluoro-7-chlo-4-oxo-1,4-dihydro-quinoline-3-carboxylate or 1-cyclopropyl-6-fluoro-7-chlo-4-oxo-1,4-dihydro-quinoline-3-carboxylate with piperazine (or N-ethyl piperazine); and then, performing after-treatment to prepare a corresponding target product norfloxacin (or ciprofloxacin or enrofloxacin). The preparation method disclosed by the invention is short in reaction step, convenient to operate, less investment and beneficial to industrial production; consumption of piperazine (or N-ethyl piperazine) can be reduced by more than half; under the catalytic action, the reaction temperature is low, the byproducts are less, the yield is high and the cost is low; heavy use of inorganic acid and inorganic alkaline is avoided, so that the pollution is reduced.
